A Comprehensive Review on Aphthous Stomatitis, Its Types, Management and Treatment Available Sharma D1,2* and Garg R3 1Ph.D
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Use of Biologic Agents in the Treatment of Oral Lesions Due to Pemphigus and Behçet's Disease: a Systematic Review
Davis GE, Sarandev G, Vaughan AT, Al-Eryani K, Enciso R. The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review. J Anesthesiol & Pain Therapy. 2020;1(1):14-23 Systematic Review Open Access The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review Gerald E. Davis II1,2, George Sarandev1, Alexander T. Vaughan1, Kamal Al-Eryani3, Reyes Enciso4* 1Advanced graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 2Assistant Dean of Academic Affairs, Assistant Professor, Restorative Dentistry, Meharry Medical College, School of Dentistry, Nashville, Tennessee, USA 3Assistant Professor of Clinical Dentistry, Division of Periodontology, Dental Hygiene & Diagnostic Sciences, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 4Associate Professor (Instructional), Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA Article Info Abstract Article Notes Background: Current treatments for pemphigus and Behçet’s disease, such Received: : March 11, 2019 as corticosteroids, have long-term serious adverse effects. Accepted: : April 29, 2020 Objective: The objective of this systematic review was to evaluate the *Correspondence: efficacy of biologic agents (biopharmaceuticals manufactured via a biological *Dr. Reyes Enciso, Associate Professor (Instructional), Division source) on the treatment of intraoral lesions associated with pemphigus and of Dental Public Health and Pediatric Dentistry, Herman Ostrow Behçet’s disease compared to glucocorticoids or placebo. School of Dentistry of USC, Los Angeles, California, USA; Email: [email protected]. -
Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis 1Joanna Baptist, 2Shrijana Shakya, 3Ravikiran Ongole
JCDP Rebamipide to Manage Stomatopyrosis10.5005/jp-journals-10024-1972 in Oral Submucous Fibrosis ORIGINAL RESEARCH Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis 1Joanna Baptist, 2Shrijana Shakya, 3Ravikiran Ongole ABSTRACT Source of support: Nil Introduction: Oral submucous fibrosis (OSF) causes progres- Conflict of interest: None sive debilitating symptoms, such as oral burning sensation (sto- matopyrosis) and limited mouth opening. The standard of care INTRODUCTION (SOC) protocol includes habit cessation, intralesional steroid and hyaluronidase injections, and mouth opening exercises. The Oral submucous fibrosis (OSF) is commonly seen in objective of the study was to evaluate efficacy of rebamipide the Indian subcontinent affecting individuals of all age in alleviating burning sensation of the oral mucosa in OSF in groups. It is a potentially malignant disorder caused comparison with SOC intralesional steroid injections. almost exclusively by the use of smokeless form of Materials and methods: Twenty OSF patients were divided into tobacco products. The malignant transformation rates two groups [rebamipide (100 mg TID for 21 days) and betametha- vary from 3 to 19%.1,2 sone (4 mg/mL biweekly for 4 weeks)] of 10 each by random Oral submucous fibrosis causes progressive debilitat- sampling. Burning sensation was assessed every week for 1 month. Burning sensation scores were analyzed using repeated ing symptoms affecting the oral cavity, such as burning measures analysis of variance (ANOVA) and paired t-test. sensation, loss of cheek elasticity, restricted tongue move- Results: Change in burning sensation score was significant ments, and limited mouth opening. Oral submucous (p < 0.05) in the first four visits. However, score between the fibrosis is an irreversible condition and the management 4th and 5th visit was not statistically significant (p > 0.05). -
Management of Oral Submucous Fibrosis – an Update
European Journal of Molecular & Clinical Medicine ISSN 2515-8260 Volume 07, Issue 5, 2020 Management Of Oral Submucous Fibrosis – An Update Aishwarya V1; Dr. A. Amudhan2, Dr. A. Amudhan Professor, Dept. of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. 1. Undergraduate student, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. 2. Professor, Dept of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. Professor, Dept. of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. Email ID: [email protected] ABSTRACT: Oral submucous fibrosis (OSF) is an insidious, chronic, progressive, debilitating disease. It is mostly prevalent in the South-east Asian countries. Areca nut chewing usually causes the condition. The hallmark of the disease being sub mucosal fibrosis that affects most parts of the oral cavity, pharynx and upper third of the oesophagus and its clinical presentation depends on the stage of the disease at detection. As the disease has a spectrum of presentation, the management differs with the various stages of the disease. This article reviews the various medical management techniques of oral submucous fibrosis. KEYWORDS: Arecanut; Etiopathogenesis; Management; Oral submucous fibrosis INTRODUCTION: Oral submucous fibrosis was first described -
Caudal Stomatitis and Other Autoimmune Oral Disease
Caudal Stomatitis and Other Autoimmune Oral Disease Yuck, no practitioner wants to deal with these cases… But treating these will benefit your patients Autoimmune Oral Disease Multiple expressions of over response of the immune system Most common are; Caudal Stomatitis Chronic Ulcerative Paradental Stomatitis Juvenile Periodontitis Caudal Stomatitis Primarily in feline patients Hallmarks in history: Oral pain Dysphagia Ptyalism Vocalizing Distinct halitosis Diagnosis of Caudal Stomatitis Primarily a diagnosis of history and oral evaluation Oral evaluation hallmarks Palatitis Glossitis Mucositis PALATOGLOSSAL FOLD PROLIFERATION, ULCERATION Other useful diagnostic tools Hypergammaglobulinemia Bartonella titer (this is of questionable clinical relevance) Histopathology almost always shows lymphoplasmacytic infiltrate with mild to moderate fibrosis Some neutrophilic infiltrate is common WHEN IN DOUBT, SUBMIT INCISIONAL BIOPSY Pathogenesis Well…This is really up for grabs. Thought to be auto-antibodies directed at the periodontal ligament There are certainly multiple etiologies and much needs to be elucidated Probable Caudal Stomatitis Unlikely Caudal Stomatitis OK, this is the big one THERAPY OF CAUDAL STOMATITIS Divide therapy into acute therapy directed at return to eating and definitive therapy directed at long term analgesia and return to function THERE IS NO CURE, WE ARE TREATING SYMPTOMS Acute Therapy 1. In anorexic, painful cats a. Analgesics 1. Opioids 2. Non-steroidal anti-inflammatories 3. Oral antibiotics -
2017 Oregon Dental Conference® Course Handout
2017 Oregon Dental Conference® Course Handout Nasser Said-Al-Naief, DDS, MS Course 8125: “The Mouth as The Body’s Mirror: Oral, Maxillofacial, and Head and Neck Manifestations of Systemic Disease” Thursday, April 6 2 pm - 3:30 pm 2/28/2017 The Mouth as The Body’s Mirror Oral Maxillofacial and Head and Neck Manifestation of Ulcerative Conditions of Allergic & Immunological Systemic Disease the Oro-Maxillofacial Diseases Region Nasser Said-Al-Naief, DDS, MS Professor & Chair, Oral Pathology and Radiology Director, OMFP Laboratory Oral manifestations of Office 503-494-8904// Direct: 503-494-0041 systemic diseases Oral Manifestations of Fax: 503-494-8905 Dermatological Diseases Cell: 1-205-215-5699 Common Oral [email protected] Conditions [email protected] OHSU School of Dentistry OHSU School of Medicine 2730 SW Moody Ave, CLSB 5N008 Portland, Oregon 97201 Recurrent aphthous stomatitis (RAS) Recurrent aphthous stomatitis (RAS) • Aphthous" comes from the Greek word "aphtha”- • Recurrence of one or more painful oral ulcers, in periods of days months. = ulcer • Usually begins in childhood or adolescence, • The most common oral mucosal disease in North • May decrease in frequency and severity by age America. (30+). • Affect 5% to 66% of the North American • Ulcers are confined to the lining (non-keratinized) population. mucosa: • * 60% of those affected are members of the • Buccal/labial mucosa, lateral/ventral tongue/floor of professional class. the mouth, soft palate/oropharyngeal mucosa • Etiopathogenesis: 1 2/28/2017 Etiology of RAU Recurrent Aphthous Stomatitis (RAS): Types: Minor; small size, shallow, regular, preceeded by prodrome, heal in 7-10 days Bacteria ( S. -
Oral Manifestations of Systemic Disease Their Clinical Practice
ARTICLE Oral manifestations of systemic disease ©corbac40/iStock/Getty Plus Images S. R. Porter,1 V. Mercadente2 and S. Fedele3 provide a succinct review of oral mucosal and salivary gland disorders that may arise as a consequence of systemic disease. While the majority of disorders of the mouth are centred upon the focus of therapy; and/or 3) the dominant cause of a lessening of the direct action of plaque, the oral tissues can be subject to change affected person’s quality of life. The oral features that an oral healthcare or damage as a consequence of disease that predominantly affects provider may witness will often be dependent upon the nature of other body systems. Such oral manifestations of systemic disease their clinical practice. For example, specialists of paediatric dentistry can be highly variable in both frequency and presentation. As and orthodontics are likely to encounter the oral features of patients lifespan increases and medical care becomes ever more complex with congenital disease while those specialties allied to disease of and effective it is likely that the numbers of individuals with adulthood may see manifestations of infectious, immunologically- oral manifestations of systemic disease will continue to rise. mediated or malignant disease. The present article aims to provide This article provides a succinct review of oral manifestations a succinct review of the oral manifestations of systemic disease of of systemic disease. It focuses upon oral mucosal and salivary patients likely to attend oral medicine services. The review will focus gland disorders that may arise as a consequence of systemic upon disorders affecting the oral mucosa and salivary glands – as disease. -
Amlexanox TBK1 & Ikke Inhibitor Catalog # Inh-Amx
Amlexanox TBK1 & IKKe inhibitor Catalog # inh-amx For research use only Version # 15I29-MM PRODUCT INFORMATION METHODS Contents: Preparation of 10 mg/ml (33.5 mM) stock solution • 50 mg Amlexanox 1- Weigh 10 mg of Amlexanox Storage and stability: 2- Add 1 ml of DMSO to 10 mg Amlexanox. Mix by vortexing. - Amlexanox is provided lyophilized and shipped at room temperature. 3- Prepare further dilutions using endotoxin-free water. Store at -20 °C. Lyophilized Amlexanox is stable for at least 2 years when properly stored. Working concentration: 1-300 μg/ml for cell culture assays - Upon resuspension, prepare aliquots of Amlexanox and store at -20 °C. Resuspended Amlexanox is stable for 6 months when properly stored. TBK1/IKKe inhibition: Quality control: Amlexanox can be used to assess the role of TBK1/IKKe using cellular - Purity ≥97% (UHPLC) assays, as described below in B16-Blue™ ISG cells. - The inhibitory activity of this product has been validated using cellular 1- Prepare a B16-Blue™ ISG cell suspension at ~500,000 cells/ml. assays. 2- Add 160 µl of cell suspension (~75,000 cells) per well. - The absence of bacterial contamination (e.g. lipoproteins and 3- Add 20 µl of Amlexanox 30-300 µg/ml (final concentration) and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ incubate at 37 °C for 1 hour. TLR4 cells. 4-Add 20 µl of sample per well of a flat-bottom 96-well plate. Note: We recommend using a positive control such as 5’ppp-dsRNA delivered intracellularly with LyoVec™ . DESCRIPTION 5- Incubate the plate at 37 °C in a 5% CO incubator for 18-24 hours. -
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine -
PRACTICAL CLINICAL COURSES V3969 Common Frustrating Oral
PRACTICAL CLINICAL COURSES A Service of the Gordon J. Christensen Career Development Program V3969 Common Frustrating Oral Diseases – Diagnosis & Treatment John A. Svirsky, DDS, MEd Gordon J. Christensen, DDS, MSD, PhD Materials Included C.E. Instruction Sheet Products List Clinician Responsible Goals & Objectives Overview References AGD Post-Test Non-SLS Toothpastes Therapy – Treatments 1 Gordon J. Christensen PRACTICAL CLINICAL COURSES PROCEDURE FOR RECEIVING ACADEMY OF GENERAL DENTISTRY AND STATE CREDIT FOR DVDS 1. Complete the enclosed Post-Test.* For each CE Video Purchased, one test is included. If additional tests are needed, the following fees will apply: $25 per test for 1 additional dentist; $10 per test for each auxiliary (dental assistants, hygienists, lab technicians - no limit on auxiliary tests). Fees can be paid either by check or credit card when tests are submitted to Practical Clinical Courses. 2. Complete the demographic information located at the end of the test. Type of Credit: a. If the applicant selects “State,” PCC will send a certificate of verification to the applicant. The applicant must then submit this certificate to his/her state board to obtain credit. b. If the applicant selects “AGD,” PCC will submit credit information to the Academy of General Dentistry and confirmation to the applicant that it has been submitted. (The applicant may check their AGD transcript for verification – please allow 30 days.) c. If the applicant selects “Both,” PCC will complete a. & b. above. 3. Return the Post-Test portion via mail, fax, or email. Our contact information is as follows: Practical Clinical Courses 3707 N Canyon Road Suite 3D Provo, UT 84604 Fax: (801) 226-8637 [email protected] 4. -
Distribution of Oral Ulceration Cases in Oral Medicine Integrated Installation of Universitas Padjadjaran Dental Hospital
Padjadjaran Journal of Dentistry. 2020;32(3):237-242. Distribution of oral ulceration cases in Oral Medicine Integrated Installation of Universitas Padjadjaran Dental Hospital Dewi Zakiawati1*, Nanan Nur'aeny1, Riani Setiadhi1 1*Department of Oral Medicine, Faculty of Dentistry Universitas Padjadjaran, Indonesia ABSTRACT Introduction: Oral ulceration defines as discontinuity of the oral mucosa caused by the damage of both epithelium and lamina propria. Among other types of lesions, ulceration is the most commonly found lesion in the oral mucosa, especially in the outpatient unit. Oral Medicine Integrated Installation (OMII) Department in Universitas Padjadjaran Dental Hospital serves as the centre of oral health and education services, particularly in handling outpatient oral medicine cases. This research was the first study done in the Department which aimed to observe the distribution of oral ulceration in OMII Department university Dental Hospital. The data is essential in studying the epidemiology of the diseases. Methods: The research was a descriptive study using the patient’s medical data between 2010 and 2012. The data were recorded with Microsoft® Excel, then analysed and presented in the table and diagram using GraphPad Prism® Results: During the study, the distribution of oral ulceration cases found in OMII Department was 664 which comprises of traumatic ulcers, recurrent aphthous stomatitis, angular cheilitis, herpes simplex, herpes labialis, and herpes zoster. Additionally, more than 50% of the total case was recurrent aphthous stomatitis, with a precise number of 364. Conclusion: It can be concluded that the OMII Department in university Dental Hospital had been managing various oral ulceration cases, with the most abundant cases being recurrent aphthous stomatitis. -
Clinical Significance of Dental Anatomy, Histology, Physiology, and Occlusion
1 Clinical Significance of Dental Anatomy, Histology, Physiology, and Occlusion LEE W. BOUSHELL, JOHN R. STURDEVANT thorough understanding of the histology, physiology, and Incisors are essential for proper esthetics of the smile, facial soft occlusal interactions of the dentition and supporting tissues tissue contours (e.g., lip support), and speech (phonetics). is essential for the restorative dentist. Knowledge of the structuresA of teeth (enamel, dentin, cementum, and pulp) and Canines their relationships to each other and to the supporting structures Canines possess the longest roots of all teeth and are located at is necessary, especially when treating dental caries. The protective the corners of the dental arches. They function in the seizing, function of the tooth form is revealed by its impact on masticatory piercing, tearing, and cutting of food. From a proximal view, the muscle activity, the supporting tissues (osseous and mucosal), and crown also has a triangular shape, with a thick incisal ridge. The the pulp. Proper tooth form contributes to healthy supporting anatomic form of the crown and the length of the root make tissues. The contour and contact relationships of teeth with adjacent canine teeth strong, stable abutments for fixed or removable and opposing teeth are major determinants of muscle function in prostheses. Canines not only serve as important guides in occlusion, mastication, esthetics, speech, and protection. The relationships because of their anchorage and position in the dental arches, but of form to function are especially noteworthy when considering also play a crucial role (along with the incisors) in the esthetics of the shape of the dental arch, proximal contacts, occlusal contacts, the smile and lip support. -
Clinical PRACTICE Blistering Mucocutaneous Diseases of the Oral Mucosa — a Review: Part 2
Clinical PRACTICE Blistering Mucocutaneous Diseases of the Oral Mucosa — A Review: Part 2. Pemphigus Vulgaris Contact Author Mark R. Darling, MSc (Dent), MSc (Med), MChD (Oral Path); Dr.Darling Tom Daley, DDS, MSc, FRCD(C) Email: mark.darling@schulich. uwo.ca ABSTRACT Oral mucous membranes may be affected by a variety of blistering mucocutaneous diseases. In this paper, we review the clinical manifestations, typical microscopic and immunofluorescence features, pathogenesis, biological behaviour and treatment of pemphigus vulgaris. Although pemphigus vulgaris is not a common disease of the oral cavity, its potential to cause severe or life-threatening disease is such that the general dentist must have an understanding of its pathophysiology, clinical presentation and management. © J Can Dent Assoc 2006; 72(1):63–6 MeSH Key Words: mouth diseases; pemphigus/drug therapy; pemphigus/etiology This article has been peer reviewed. he most common blistering conditions captopril, phenacetin, furosemide, penicillin, of the oral and perioral soft tissues were tiopronin and sulfones such as dapsone. Oral Tbriefly reviewed in part 1 of this paper lesions are commonly seen with pemphigus (viral infections, immunopathogenic mucocu- vulgaris and paraneoplastic pemphigus.6 taneous blistering diseases, erythema multi- forme and other contact or systemic allergic Normal Desmosomes reactions).1–4 This paper (part 2) focuses on Adjacent epithelial cells share a number of the second most common chronic immuno- connections including tight junctions, gap pathogenic disease to cause chronic oral junctions and desmosomes. Desmosomes are blistering: pemphigus vulgaris. specialized structures that can be thought of as spot welds between cells. The intermediate Pemphigus keratin filaments of each cell are linked to focal Pemphigus is a group of diseases associated plaque-like electron dense thickenings on the with intraepithelial blistering.5 Pemphigus inside of the cell membrane containing pro- vulgaris (variant: pemphigus vegetans) and teins called plakoglobins and desmoplakins.